Abstracts tagged "T cells and metabolism"

Abstract Number: 2638 • 2017 ACR/ARHP Annual Meeting
Inducible cAMP Early Repressor Promotes Glycolysis By Inhibiting the Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 2 in Th17 Cells
Michihito Kono, Nobuya Yoshida, Nicole E. Skinner and George C. Tsokos, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Th17 cells are key players in SLE. Because Th17 cells use mainly glycolysis, blocking glycolysis can inhibit Th17 cell differentiation and treatment of lupus-prone…
Abstract Number: 1828 • 2016 ACR/ARHP Annual Meeting
Metabolic Reprogramming in CD4+CD28-CXCR3intt-bethi cells and Its Relevance to Pathogenesis in Patients with SLE
Shigeru Iwata¹, Yuka Kanno², Kei Sakata^3,4, Maiko Hajime¹, Masataka Torigoe^1,5, Naoaki Ohkubo¹, Shingo Nakayamada⁶, John J O'Shea⁷ and Yoshiya Tanaka⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyshu, Japan, ⁵Department of Endocrinology, Metabolism, Rheumatology and Nephrology,, Faculty of Medicine, Oita University, Yufu, Oita, Japan, Yufu, Japan, ⁶First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: CD4+ T cells play a crucial role in pathological process of Systemic Lupus Erythematosus (SLE). Recently, importance of metabolic reprograming in immunocompetent cells was…
Abstract Number: 996 • 2015 ACR/ARHP Annual Meeting
Metabolic Control of Invariant Natural Killer T Cell Function
Kevin Wei¹, Deepak A. Rao², Pui Y. Lee³, Anqi Gao⁴, Peter A. Nigrovic⁵ and Michael Brenner⁶, ¹Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ²Internal Medicine/Rheumatology, Brigham & Womens Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Invariant Natural Killer T (iNKT) cells are a unique subset of T cells that shape an inflammatory response through rapid production of large amounts…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].